Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLady Davis Institute

About this trial

Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. The investigators plan to conduct a series of randomized controlled trials among people with scleroderma, a rare autoimmune disease, in a large international cohort, to identify the most effective methods for communicating study results with patients.

The first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator. Participants will be randomly assigned to receive the dissemination tool or comparator. Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. Our results can be used by researchers and patient organizations who disseminate research results so that they can tailor the way they disseminate results to patient needs.

Eligibility criteria

Qualifiers

Enrollment in SPIN Cohort, which requires a systemic sclerosis (SSc) classification by a site physician based on 2013 American College of Rheumatology/European League Against Rheumatism criteria, ≥18 years old, being fluent in English or French, and have completed one SPIN Cohort assessment in the last year.

External enrollment with patient-reported physician classification of SSc and age 18 or older.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Plain-language summary
  • Dissemination Tool (Infographic)

Treatment groups

128 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators